Nucleic Acids Research Advance Access originally published online on July 7, 2009
Nucleic Acids Research 2009 37(16):5405-5419; doi:10.1093/nar/gkp548
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2009, Vol. 37, No. 16 5405-5419
© 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nucleic Acid Enzymes |
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease
1Cellectis S.A., 2Cellectis Genome Surgery, 102 Avenue Gustave Roussel, 93235 Romainville, France, 3Structural Biology and Biocomputing Program, Spanish National Cancer Center (CNIO), Macromolecular Crystallography Group, Melchor Fdez. Almagro 3, 28029 Madrid and 4Structural Biology Unit, CIC bioGUNE, Parque Tecnológico de Vizcaya, Edificio 800 48160, Derio, Spain
*To whom correspondence should be addressed. Tel: 33 1 41 83 99 14; Fax: 33 1 41 83 99 03; Email: paques{at}cellectis.com
Received May 5, 2009. Revised June 10, 2009. Accepted June 11, 2009.
Sequence-specific endonucleases recognizing long target sequences are emerging as powerful tools for genome engineering. These endonucleases could be used to correct deleterious mutations or to inactivate viruses, in a new approach to molecular medicine. However, such applications are highly demanding in terms of safety. Mutations in the human RAG1 gene cause severe combined immunodeficiency (SCID). Using the I-CreI dimeric LAGLIDADG meganuclease as a scaffold, we describe here the engineering of a series of endonucleases cleaving the human RAG1 gene, including obligate heterodimers and single-chain molecules. We show that a novel single-chain design, in which two different monomers are linked to form a single molecule, can induce high levels of recombination while safeguarding more effectively against potential genotoxicity. We provide here the first demonstration that an engineered meganuclease can induce targeted recombination at an endogenous locus in up to 6% of transfected human cells. These properties rank this new generation of endonucleases among the best molecular scissors available for genome surgery strategies, potentially avoiding the deleterious effects of previous gene therapy approaches.
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.